CD8 (cluster of differentiation 8) is a transmembrane glycoprotein that serves as a co-receptor for the T cell receptor (TCR). Like the TCR, CD8 binds to a major histocompatibility complex (MHC) molecule, but is specific for the class I MHC protein.[2] There are two isoforms of the protein, alpha and beta, each encoded by a different gene. In humans, both genes are located on chromosome 2 in position 2p12.
Tumor infiltrating lymphocytes (TILs) are a type of white blood cell found in tumors. TILs are implicated in killing tumor cells, and the presence of lymphocytes in tumors is often associated with better clinical outcomes
$ONCS pursuit of optimizing CD8 TILs via identification markers could possibly lead to increased ORR of EP+IL-12 varied dosages specific for each individual Cancer recipient.
Excellent post lasers! Wouldn't it be sweet if yesterday's data was significant enough to be submitted as a late breaking abstract for ASCO? One can always hope! I DO find it interesting that the announcement of doing this presentation was not part of the PR at the beginning of the month referencing "May presentations"....almost as if they decided recently to present there?
News 
Market Data 
Discover 
